Treatment Action Group (TAG) seeks a dynamic, motivated, and skilled individual to become its Director of Development supporting the organization as it continues to grow.
Treatment Action Group (TAG) is pleased to announce that two new members have been elected to the Board of Directors, Ama Burnham and Dr. Stefan V. Goldberg.
Treatment Action Group (TAG) is proud to be one of the organizational sponsors of SYNChronicity 2024 (SYNC 2024). This annual national conference for HIV, HCV, STIs, harm reduction, and LGBTQ health will be held in Arlington, Virginia, from May 29 – 31; more than 1500 attendees are expected to participate.
Save the Date: Thursday, October 17, 2024, when our Research in Action Awards return this fall! Once again we'll honor some of the most brilliant activists, scientists, and leaders in the fight to end HIV, tuberculosis (TB), and hepatitis C (HCV).
Treatment Action Group (TAG), the New-York-City-based activist research and policy think tank working to end the epidemics of HIV, TB, and hepatitis C, made leadership changes at its annual Board of Directors meeting on February 10, 2024.
We are appalled. As organisations that have historically worked on issues of health justice and access to medicines for millions of people around the world, for decades, focusing on HIV/AIDS, TB, cancer, and COVID, we share the urgent concern and outrage of aid organizations (NGOs) that the sudden decision by global north donor countries to suspend funding for the United Nations Relief and Works Agency (UNRWA) ‘’comes amid a rapidly worsening humanitarian catastrophe in Gaza."
Hepatitis C-related liver diseases continue to kill an estimated 15,000 people per year in the United States, despite the availability of an effective cure.
This publication explores the role of community engagement in health-related research and development (R&D), particularly within the Unitaid-funded LONGEVITY Project.